Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy

Case report and review of the literature

Shinsuke Funakoshi, Akinori Hashiguchi, Kana Teramoto, Naoteru Miyata, Satoshi Kurita, Masayuki Adachi, Yasuo Hamamoto, Hajime Higuchi, Hiromasa Takaishi, Toshifumi Hibi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). SCNEC follows an aggressive clinical course and has a poor prognosis despite multidisciplinary therapies. A standard therapeutic strategy, including surgery, radiation and first-/second-line chemotherapy, has not yet been established for SCNEC. We present a case of SCNEC of the esophagus. A 66-year-old male with SCNEC as extensive disease was treated with 60 mg/m2 cisplatin on day 1 plus 60 mg/m2 irinotecan on days 1, 8 and 15 every 4 weeks (IP) with successful complete remission. After the sixth course of IP, increasing pro-gastrin-releasing peptide (ProGRP) and nonspecific enolase (NSE) levels and intense fluorodeoxyglucose (FDG) avidity in a lymph node around the celiac artery (SUVmax, 8.3) indicated a refractory relapse of the disease. The patient was treated with three courses of amrubicin (AMR, 35 mg/m2) administered intravenously for 3 consecutive days every 3 weeks as a second-line chemotherapy. The ProGRP and NSE levels returned to the normal range 1 month after the initiation of second-line chemotherapy. However, the ProGRP and NSE levels were elevated after the third course of AMR, and PET-CT revealed progressive disease with liver metastasis and extended lymph node metastasis. As the patient remained asymptomatic, paclitaxel (100 mg/m2) was started as third-line chemotherapy. Patients with SCNEC of the esophagus with extensive disease should be treated with aggressive chemotherapy rather than surgery or radiation monotherapy. In the present case, tumor markers such as ProGRP and NSE were predictive of relapse and PET-CT was used to detect relapse. Further research is required to identify and exploit promising agents for resistant SCNEC.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalOncology Letters
Volume5
Issue number1
DOIs
Publication statusPublished - 2012

Fingerprint

irinotecan
Neuroendocrine Carcinoma
Small Cell Carcinoma
Cisplatin
Esophagus
Gastrin-Releasing Peptide
Drug Therapy
Phosphopyruvate Hydratase
Therapeutics
Recurrence
Lymph Nodes
Radiation
Celiac Artery
Neoplasm Metastasis
Tumor Biomarkers
Paclitaxel

Keywords

  • Amrubicin
  • Fluorodeoxyglucose positron emission tomography/computed tomography
  • IP
  • Ki-67
  • Small cell neuroendocrine carcinoma
  • WHO classification

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy : Case report and review of the literature. / Funakoshi, Shinsuke; Hashiguchi, Akinori; Teramoto, Kana; Miyata, Naoteru; Kurita, Satoshi; Adachi, Masayuki; Hamamoto, Yasuo; Higuchi, Hajime; Takaishi, Hiromasa; Hibi, Toshifumi.

In: Oncology Letters, Vol. 5, No. 1, 2012, p. 117-122.

Research output: Contribution to journalArticle

@article{b39ba2d2737f4d54aa5ff963b8353ee0,
title = "Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature",
abstract = "Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). SCNEC follows an aggressive clinical course and has a poor prognosis despite multidisciplinary therapies. A standard therapeutic strategy, including surgery, radiation and first-/second-line chemotherapy, has not yet been established for SCNEC. We present a case of SCNEC of the esophagus. A 66-year-old male with SCNEC as extensive disease was treated with 60 mg/m2 cisplatin on day 1 plus 60 mg/m2 irinotecan on days 1, 8 and 15 every 4 weeks (IP) with successful complete remission. After the sixth course of IP, increasing pro-gastrin-releasing peptide (ProGRP) and nonspecific enolase (NSE) levels and intense fluorodeoxyglucose (FDG) avidity in a lymph node around the celiac artery (SUVmax, 8.3) indicated a refractory relapse of the disease. The patient was treated with three courses of amrubicin (AMR, 35 mg/m2) administered intravenously for 3 consecutive days every 3 weeks as a second-line chemotherapy. The ProGRP and NSE levels returned to the normal range 1 month after the initiation of second-line chemotherapy. However, the ProGRP and NSE levels were elevated after the third course of AMR, and PET-CT revealed progressive disease with liver metastasis and extended lymph node metastasis. As the patient remained asymptomatic, paclitaxel (100 mg/m2) was started as third-line chemotherapy. Patients with SCNEC of the esophagus with extensive disease should be treated with aggressive chemotherapy rather than surgery or radiation monotherapy. In the present case, tumor markers such as ProGRP and NSE were predictive of relapse and PET-CT was used to detect relapse. Further research is required to identify and exploit promising agents for resistant SCNEC.",
keywords = "Amrubicin, Fluorodeoxyglucose positron emission tomography/computed tomography, IP, Ki-67, Small cell neuroendocrine carcinoma, WHO classification",
author = "Shinsuke Funakoshi and Akinori Hashiguchi and Kana Teramoto and Naoteru Miyata and Satoshi Kurita and Masayuki Adachi and Yasuo Hamamoto and Hajime Higuchi and Hiromasa Takaishi and Toshifumi Hibi",
year = "2012",
doi = "10.3892/ol.2012.1008",
language = "English",
volume = "5",
pages = "117--122",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy

T2 - Case report and review of the literature

AU - Funakoshi, Shinsuke

AU - Hashiguchi, Akinori

AU - Teramoto, Kana

AU - Miyata, Naoteru

AU - Kurita, Satoshi

AU - Adachi, Masayuki

AU - Hamamoto, Yasuo

AU - Higuchi, Hajime

AU - Takaishi, Hiromasa

AU - Hibi, Toshifumi

PY - 2012

Y1 - 2012

N2 - Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). SCNEC follows an aggressive clinical course and has a poor prognosis despite multidisciplinary therapies. A standard therapeutic strategy, including surgery, radiation and first-/second-line chemotherapy, has not yet been established for SCNEC. We present a case of SCNEC of the esophagus. A 66-year-old male with SCNEC as extensive disease was treated with 60 mg/m2 cisplatin on day 1 plus 60 mg/m2 irinotecan on days 1, 8 and 15 every 4 weeks (IP) with successful complete remission. After the sixth course of IP, increasing pro-gastrin-releasing peptide (ProGRP) and nonspecific enolase (NSE) levels and intense fluorodeoxyglucose (FDG) avidity in a lymph node around the celiac artery (SUVmax, 8.3) indicated a refractory relapse of the disease. The patient was treated with three courses of amrubicin (AMR, 35 mg/m2) administered intravenously for 3 consecutive days every 3 weeks as a second-line chemotherapy. The ProGRP and NSE levels returned to the normal range 1 month after the initiation of second-line chemotherapy. However, the ProGRP and NSE levels were elevated after the third course of AMR, and PET-CT revealed progressive disease with liver metastasis and extended lymph node metastasis. As the patient remained asymptomatic, paclitaxel (100 mg/m2) was started as third-line chemotherapy. Patients with SCNEC of the esophagus with extensive disease should be treated with aggressive chemotherapy rather than surgery or radiation monotherapy. In the present case, tumor markers such as ProGRP and NSE were predictive of relapse and PET-CT was used to detect relapse. Further research is required to identify and exploit promising agents for resistant SCNEC.

AB - Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). SCNEC follows an aggressive clinical course and has a poor prognosis despite multidisciplinary therapies. A standard therapeutic strategy, including surgery, radiation and first-/second-line chemotherapy, has not yet been established for SCNEC. We present a case of SCNEC of the esophagus. A 66-year-old male with SCNEC as extensive disease was treated with 60 mg/m2 cisplatin on day 1 plus 60 mg/m2 irinotecan on days 1, 8 and 15 every 4 weeks (IP) with successful complete remission. After the sixth course of IP, increasing pro-gastrin-releasing peptide (ProGRP) and nonspecific enolase (NSE) levels and intense fluorodeoxyglucose (FDG) avidity in a lymph node around the celiac artery (SUVmax, 8.3) indicated a refractory relapse of the disease. The patient was treated with three courses of amrubicin (AMR, 35 mg/m2) administered intravenously for 3 consecutive days every 3 weeks as a second-line chemotherapy. The ProGRP and NSE levels returned to the normal range 1 month after the initiation of second-line chemotherapy. However, the ProGRP and NSE levels were elevated after the third course of AMR, and PET-CT revealed progressive disease with liver metastasis and extended lymph node metastasis. As the patient remained asymptomatic, paclitaxel (100 mg/m2) was started as third-line chemotherapy. Patients with SCNEC of the esophagus with extensive disease should be treated with aggressive chemotherapy rather than surgery or radiation monotherapy. In the present case, tumor markers such as ProGRP and NSE were predictive of relapse and PET-CT was used to detect relapse. Further research is required to identify and exploit promising agents for resistant SCNEC.

KW - Amrubicin

KW - Fluorodeoxyglucose positron emission tomography/computed tomography

KW - IP

KW - Ki-67

KW - Small cell neuroendocrine carcinoma

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=84869020042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869020042&partnerID=8YFLogxK

U2 - 10.3892/ol.2012.1008

DO - 10.3892/ol.2012.1008

M3 - Article

VL - 5

SP - 117

EP - 122

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -